Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Completed · Phase 3

Conditions studied: Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain

In brief

The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.

Key facts

Study ID

NCT00984815

Run by

Amgen

People needed

86

Starts

2009-09-01

Expected to finish

2011-07-01

Last updated by the study team

2024-12-18

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.
• Patient is male or female, aged 40 to 80 years of age.
• Patient is expected to require daily administration of an NSAID for at least the coming year for conditions including but not limited to: osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, chronic soft tissue pain.
• Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the entire study period.
• Patient is willing and able to comply with the prescribed treatment protocol and evaluations.

You may not qualify if…

• Patient has a history of or experienced any of the following:
• NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding
• NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis
• Malignant disease of the gastrointestinal tract
• Erosive esophagitis
• Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0
• Uncontrolled diabetes mellitus as evidenced by Hemoglobin A1c > 7%
• Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C
• Patient has active cardiac, renal, and/or hepatic disease, as evidenced by:
• Creatinine clearance < 45 mL/min (based on the Cockroft-Gault formula) at Screening
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at Screening
• History of acute myocardial infarction, unstable cardiac arrhythmias, and/or stroke within the 6 months prior to study entry
• Uncontrolled congestive heart failure
• Uncontrolled hypertension
• Patient currently is participating in an investigational drug study, or patient participated in an investigational drug study within the 30 days prior to study entry.
• Female patient has a positive urine pregnancy test at Screening and/or Study Day 0.
• Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk.

Where it is running

• University of Illinois Medical Center, Department of Medicine — Chicago, Illinois, United States
• Illinois Bone & Joint Institute — Morton Grove, Illinois, United States
• Altoona Center for Clinical Research Altoona Arthritis — Duncansville, Pennsylvania, United States
• Metroplex Clinical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.